The antipruritic effect of 5% doxepin cream in patients with eczematous dermatitis. Doxepin Study Group

Drake, L. A.

doi:10.1001/archderm.131.12.1403

Cited by 27 publications

(24 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Menthol is a benign agent with minimal side effects which can be used concurrently with systemic agents to relieve rash and itch [46]. Topical and oral doxepin have been found to relieve pruritus in the general patient population [47–49]. At this time, it is unknown whether other topical agents, such as antihistamines, lidocaine, and calamine, will provide adequate efficacy to alleviate pruritus induced by EGFRIs.…”

Section: Results and Recommendationsmentioning

confidence: 99%

Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities

Lacouture

Anadkat²,

Bensadoun

et al. 2011

Support Care Cancer

383

393

View full text Add to dashboard Cite

BackgroundEpidermal growth factor receptor inhibitors (EGFRI) produce various dermatologic side effects in the majority of patients, and guidelines are crucial for the prevention and treatment of these untoward events. The purpose of this panel was to develop evidence-based recommendations for EGFRI-associated dermatologic toxicities.MethodsA multinational, interdisciplinary panel of experts in supportive care in cancer reviewed pertinent studies using established criteria in order to develop first-generation recommendations for EGFRI-associated dermatologic toxicities.ResultsProphylactic and reactive recommendations for papulopustular (acneiform) rash, hair changes, radiation dermatitis, pruritus, mucositis, xerosis/fissures, and paronychia are presented, as well as general dermatologic recommendations when possible.ConclusionPrevention and management of EGFRI-related dermatologic toxicities is critical to maintain patients’ health-related quality of life and dose intensity of antineoplastic regimens. More rigorous investigation of these toxicities is warranted to improve preventive and treatment strategies.Electronic supplementary materialThe online version of this article (doi:10.1007/s00520-011-1197-6) contains supplementary material, which is available to authorized users.

show abstract

Section: Results and Recommendationsmentioning

confidence: 99%

Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities

Lacouture

Anadkat²,

Bensadoun

et al. 2011

Support Care Cancer

383

393

View full text Add to dashboard Cite

show abstract

“…These topical preparations were shown to reduce pruritus in patients with AD (38). However, topical doxepin is not an appropriate therapy for the pruritus of AD, given the concerns for topical sensitization as well as systemic absorption and drowsiness (39,40). …”

Section: Topical Treatmentsmentioning

confidence: 99%

The effects of treatment on itch in atopic dermatitis

2013

View full text Add to dashboard Cite

Pruritus causes significant impairment in the quality of life of patients suffering from atopic dermatitis. Treatments for itch in atopic dermatitis range from simple avoidance of pruritus triggers to more complicated systemic therapy. Several treatments aim to target specific mediators of itch in atopic dermatitis, while others improve pruritus by reducing inflammation. Currently, the most effective treatments for atopic dermatitis-associated itch are primarily topical or systemic anti-inflammatory agents. Better management of pruritus in atopic dermatitis is an important goal, and necessitates the development of novel targeted treatments as well as efficient use of current therapies.

show abstract

“…45 Only topical doxepin, a tricyclic antidepressant and potent H1 and H2 antagonist, has been shown to significantly reduce pruritus in patients with AD, lichen simplex chronicus, contact dermatitis and nummular dermatitis. 46, 47 However, topical doxepin may cause localized burning, allergic contact dermatitis, and has been reported to cause drowsiness due to systemic absorption in up to 25% of patients. 46, 47 Thus, despite its potential benefit, use of topical doxepin is limited by its side effect profile and it is best avoided in children and used with caution in the elderly.…”

Section: Topical Antihistaminesmentioning

confidence: 99%

Topical Therapies for Pruritus

Elmariah¹,

Lerner²

2011

Seminars in Cutaneous Medicine and Surgery

View full text Add to dashboard Cite

Itch, or pruritus, is the predominant symptom associated with acute and chronic cutaneous disease and in some cases, may be debilitating. To date, there is no single universally effective anti-itch treatment. As the pathophysiology of itch in most cutaneous or systemic disorders remains unclear, anti-pruritic therapy is often directed against a variety of targets, including the epidermal barrier, immune system, or the nervous system. Topical therapy is the mainstay of dermatologic management of acute or localized itch or in patients with contraindications to systemic therapies. This review will summarize current topical therapies to treat pruritus and discuss potential future therapies.

show abstract

The antipruritic effect of 5% doxepin cream in patients with eczematous dermatitis. Doxepin Study Group

Cited by 27 publications

References 0 publications

Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities

Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities

The effects of treatment on itch in atopic dermatitis

Topical Therapies for Pruritus

Contact Info

Product

Resources

About